Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.
Open Access
- 1 April 1994
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 47 (4) , 309-312
- https://doi.org/10.1136/jcp.47.4.309
Abstract
AIMS--To determine the expression of intercellular adhesion molecule 1 and 2 (ICAM 1 and 2) in transitional cell carcinoma cells before and after immunotherapy with Calmette-Guérin bacillus (BCG). METHODS--Frozen sections from 22 untreated bladder carcinomas were immunohistochemically examined with monoclonal antibodies to ICAM 1 and 2. Urinary cytospin slides were made for six patients for each of the six clinical instillations which constitute a therapeutic course. These slides were also stained for ICAM 1 and for leucocyte function associated antigen 1 (LFA 1). RESULTS--Bladder cancer cells did not essentially express either ICAM 1 or 2, but cells in the stromal areas surrounding tumour expressed both these antigens. After repeated instillations of BCG organisms ICAM 1 positive normal and neoplastic epithelial cells were observed in the urine. Cells obtained from the first three instillations expressed lower densities of ICAM 1 than those from the later instillations. Many neutrophils expressing LFA-1 and some lymphocytes were also noted in the cytospin slides and some of these were conjugated to tumour cells expressing ICAM 1. Six months after treatment a single maintenance dose of BCG induced ICAM 1 expression. CONCLUSION--Untreated superficial bladder carcinoma cells do not express ICAM 1 or 2, but these important immunological molecules were expressed in the stromal areas of tissue. Importantly, neoplastic cells in the urine expressed ICAM 1 after immunotherapy. This molecule can render bladder tumour cells vulnerable to non-antigen specific cytotoxicity mediated by activated lymphocytes.Keywords
This publication has 25 references indexed in Scilit:
- Cell adhesion in the immune systemImmunology Today, 1993
- Expression and shedding of ICAM‐1 in bladder cancer and its immunotherapyInternational Journal of Cancer, 1993
- The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapyCancer Immunology, Immunotherapy, 1993
- Interaction of leukocyte integrins with ligand is necessary but not sufficient for function.The Journal of cell biology, 1992
- Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes.The Journal of Experimental Medicine, 1992
- The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.The Journal of Immunology, 1990
- A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinovirusesCell, 1989
- HLA—DR Expression by High Grade Superficial Bladder Cancer Treated with BCGBritish Journal of Urology, 1989
- Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells.The Journal of cell biology, 1988
- Local Immune Responses after Intravesical BCG Treatment for Carcinoma in situBritish Journal of Urology, 1987